|
|
|
|
| LEADER |
03469cam a2200421 a 4500 |
| 001 |
c000404749 |
| 003 |
CARM |
| 005 |
20190507114327.0 |
| 006 |
m d |
| 007 |
cr |n |||||||| |
| 008 |
190507s2004 enka 001 0 eng |
| 010 |
|
|
|a 2003061170
|
| 015 |
|
|
|a GBA3-U7364
|
| 019 |
1 |
|
|a 24871039
|5 LACONCORD2021
|
| 020 |
|
|
|a 0306477661 :
|c £86.25
|
| 035 |
|
|
|a (OCoLC)52853141
|5 LACONCORD2021
|
| 040 |
|
|
|a StDuBDS
|b eng
|c StDuBDS
|d Uk
|d DNLM/DLC
|
| 042 |
|
|
|a pcc
|
| 050 |
0 |
0 |
|a RM301.25
|b .A67 2004
|
| 060 |
1 |
0 |
|a QV 744
|b A6526 2004
|
| 082 |
0 |
0 |
|a 615.19
|2 22
|
| 082 |
0 |
4 |
|a 615.7
|2 21
|
| 245 |
0 |
0 |
|a Applications of pharmacokinetic principles in drug development /
|c edited by Rajesh Krishna.
|
| 260 |
|
|
|a New York ;
|a London :
|b Kluwer Academic/Plenum,
|c c2004.
|
| 300 |
|
|
|a xv, 550 p. :
|b ill. ;
|c 26 cm.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
0 |
|a Machine derived contents note: Efficient and Effective Drug Development -- Wayne A. Colburn and Gene Heath -- -- Bioanalytical Methods: Challenges and Opportunities In Drug Development 21 -- Mark L. Powell and Steve E. Unger -- -- Predicting Human Oral Bioavailability using In Silico Models 53 -- Lawrence X. Yu, Christopher D. Ellison, and Ajaz S. Hussain -- -- Drug Metabolism in Preclinical Development 75 -- Michael W. Sinz -- -- Interspecies Scaling 133 -- Thierry Lave, Olivier Luttringer, Patrick Poulin, and Neil Parrott -- -- Human Drug Absorption Studies in Early Development 177 -- David V. Prior, Alyson L. Connor, and Ian R. Wilding -- -- Food-Drug Interactions: Drug Development Considerations 195 -- David Fleisher and Laurie Reynolds -- -- Global Regulatory and Biopharmaceutics Strategies in New Drug -- Developm ent: Biowaivers 225 -- Elora Gupta and Elizabeth Yamashita -- -- Special Population Studies in Clinical Development: Pharmacokinetic -- Considerations 245 -- John M. Kovarik -- -- Drug-Drug Interactions 307 -- Shiew-Mei Huang -- -- Pharmacokinetic/Pharmacodynamic Modeling in Drug Development 333 -- Shashank Rohatagi, Nancy E. Martin, and Jeffrey S. Barrett -- -- -- -- -- Population Pharmacokinetic and Pharmacodynamic Modeling 373 -- Roger Jelliffe, Alan Schumitzky, Aida Bustad, Michael Van Guilder, -- Xin Wang, and Robert Leary -- -- Role of Preclinical Metabolism and Pharmacokinetics in the Development of -- C elecoxib 405 -- Susan K. Paulson and Timothy J. Maziasz -- -- The Role of Clinical Pharmacology and of Pharmacokinetics in the -- Development of Alendronate - A Bone Resorption Inhibitor 427 -- Arturo G. Porras and Barry J. Gertz -- -- Optimizing Individualized Dosage Regimens of Potentially Toxic Drugs 477 -- Roger W. Jelliffe, Alan Schumitzky, Robert Leary, Andreas Botnen, -- Ashutosh Gandhi, Pascal Maire, Xavier Barbaut, Nathalie Bleyzac, and -- Irina Bondareva -- -- Appendix 529 -- -- Index 545.
|
| 650 |
|
0 |
|a Drugs
|x Testing.
|
| 650 |
|
0 |
|a Pharmacokinetics.
|
| 650 |
|
0 |
|a Drug development.
|
| 700 |
1 |
|
|a Krishna, Rajesh.
|
| 852 |
8 |
|
|b CARM
|i C13773
|p 0655396
|f BK
|
| 852 |
8 |
|
|b SCAN
|h A3:AP05E0
|i C13773
|p 0655396
|f BK
|
| 852 |
8 |
|
|b SCAN
|h A3:AP05E0
|i C13773
|p 0655396
|f BK
|
| 830 |
|
0 |
|a Springer Nature Book Archives Millennium (2000-2004)
|
| 999 |
f |
f |
|i aaf0224e-ac5d-5ae2-973e-7a84dc29e00a
|s 60b6bcd2-869a-5edb-8455-5238a000e1a6
|
| 952 |
f |
f |
|p Can circulate
|a CAVAL
|b CAVAL
|c CAVAL
|d CARM 1 Store
|e C13773
|h Other scheme
|i book
|m 0655396
|
| 952 |
f |
f |
|a CAVAL
|b CAVAL
|c CAVAL
|d Unmapped Location
|e C13773
|f A3:AP05E0
|h Other scheme
|